30% OFF: As of Dec. 1, you can get 30% off Nomad eSIM plans (excluding anything already on sale) with the Mashable-exclusive discount code MASH30. This offer code is valid until the…
Blog
-
The Sony Bravia 8 OLED TV has never been cheaper, but I recommend this rival Cyber Monday deal
Black Friday has given way to Cyber Monday, and while most of the TV deals have stayed the same, the excellent Sony Bravia 8 has dropped in price even further.
Today, you can get the 55-inch Bravia 8 for £1258 at Amazon, the 65-inch model for
Continue Reading
-
Access Denied
Access Denied
You don’t have permission to access “http://www.afreximbank.com/fg-gold-afc-and-afreximbank-achieve-financial-close-on-us330-million-senior-debt-financing-for-baomahun-gold-project/” on this server.
Reference #18.cc8c655f.1764588211.a441deb3
https://errors.edgesuite.net/18.cc8c655f.1764588211.a441deb3
Continue Reading
-
mRNA Therapy Targets Multidrug-Resistant Infections
ANTIBIOTIC-resistant infections represent a growing global health threat, causing over 1.2 million deaths annually and contributing to nearly 5 million deaths worldwide. In the USA, more than 3 million infections occur each year, resulting in…
Continue Reading
-
Study Reveals The Age You Hit The ‘Tipping Point’ Into Frailty : ScienceAlert
The bumpy trajectory of human aging may have a tipping point as we enter our twilight years, a new study has found.
Past the age of around 75, our bodies can no longer easily recover from injury or illness – a sharp decline in resilience…
Continue Reading
-
Patterns of earthquakes over time in Yellowstone highlight the complexity of seismic swarms
Yellowstone Caldera Chronicles is a weekly column written by scientists and collaborators of the Yellowstone Volcano Observatory. This week’s contribution is from David Shelly, seismologist with the U.S. Geological Survey.
The Yellowstone region…
Continue Reading
-
Trump’s Net Tightens Around Maduro’s Venezuela – Bloomberg.com
- Trump’s Net Tightens Around Maduro’s Venezuela Bloomberg.com
- White House gives Maduro ultimatum as U.S. moves toward land operations Miami Herald
- Trump struggles with Venezuelan dilemma as Maduro digs in and storm builds at home over…
Continue Reading
-
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
- B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively
- Deep and durable regressions observed with IDE034 monotherapy in multiple preclinical in-vivo models with B7H3 and PTK7 co-expression
- Enhanced durability with IDE034 and IDE161 PARG inhibitor combination in preclinical in vivo models; targeting to share additional preclinical data supporting mechanistic rationale at a medical conference in H1 2026
SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 1, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC). IDEAYA expects to begin enrolling the study in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck and ovarian/gynecological cancers. Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.
“IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 ADC clinical pipeline into bispecific, precision-guided approaches,” said Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. “IDE034 has demonstrated robust antitumor activity and selective targeting of B7H3- and PTK7-expressing solid tumor models. The high prevalence of B7H3/PTK7 co-expression in solid tumors such as lung, colorectal, and head and neck cancers underscores its broad indication potential.”
“We are excited to advance our differentiated clinical strategy with now three potentially first-in-class clinical-stage programs focused on enhancing the efficacy of TOP1 ADCs through the PARG DDR combination mechanism. We believe this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies. We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
Preclinical studies have demonstrated strong anti-tumor activity in B7H3/PTK7-positive tumor models, including deep and durable tumor regressions with IDE034 monotherapy, supporting advancement into clinical development. This co-expression pattern supports the potential for broad monotherapy activity, while the TOP1 payload provides a strong mechanistic rationale for combining IDE034 with IDEAYA’s PARG inhibitor, IDE161. TOP1 inhibition induces replication stress and DNA damage, which can increase reliance on the PARG pathway; therefore, a IDE034 and IDE161 combination approach may enhance anti-tumor activity in patients with solid tumors that co-express B7H3 and PTK7, consistent with the results that were observed preclinically with this combination.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to: (i) the timing of the initiation of and enrollment of subjects for the Phase 1 clinical trial to evaluate IDE034; (ii) the potential frequency of B7H3/PTK7 co-expressed in solid tumors types, including lung, colorectal, and head and neck cancers; (iii) the potential therapeutic benefit of IDE034 as monotherapy and in combination with IDE161, a PARG inhibitor; and (iv) the timing of a data presentation related to the IDE034 and IDE161, PARG inhibitor, combination at a medical conference. Preclinical study results are not necessarily predictive of future clinical trial results and/or approval. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA’s Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]SOURCE IDEAYA Biosciences, Inc.
Continue Reading
-
DJI Cyber Monday deals include the Mic Mini kit with a charging case on sale for just $80
For such a tiny piece of tech, a good wireless microphone can have an outsize impact on the quality of your videos. If you’ve been waiting for a serious sale to pick up a mic of your own, Cyber Monday may be your chance. The DJI Mic Mini kit is…
Continue Reading
